Reports Q3 revenue $804.6M, consensus $787.7M. Eric Green, president, CEO and chair of the board, commented: “I am pleased to report that we delivered another solid quarter, with both revenues and profits exceeding our guidance. Our strength was broad-based, across both our Proprietary Products and Contract Manufacturing segments. We achieved double-digit growth in our HVP Components business, driven by our continued execution in GLP-1 products, increased HVP conversion, including Annex 1, and an overall improving demand environment. As a result of the solid performance in the quarter, and the ongoing momentum in our business, we are again increasing our full-year guidance expectations.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- Is WST a Buy, Before Earnings?
- West Pharmaceutical added to ‘Tactical Outperform’ list at Evercore ISI
- West Pharmaceutical price target raised to $275 from $260 at Barclays
- Strong Market Position and Growth Potential Justify Buy Rating for West Pharmaceutical Services
- West Pharmaceutical initiated with a Buy at Rothschild & Co Redburn